Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
ACAD vs NVS — Stock Comparison
Compare ACAD and NVS side-by-side on StoQuant: ACAD Q-Score 51 vs NVS 64; analyst signal 26 vs 52. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- ACAD — ACADIA PHARMACEUTICALS INC · Health Care · Q-Score verdict Hold (51.0, grade C) · analyst signal 26/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: valuation 83/100, earnings quality 72/100 · weakest signals: competitive moat 21/100, analyst consensus 1/100. Full ACAD research.
- NVS — Novartis AG · Health Care · market cap $287.07B · Q-Score verdict Buy (64.0, grade B) · analyst signal 52/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: technicals 95/100, analyst consensus 23/100 · weakest signals: ML forecast 16/100. Full NVS research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: ACAD research · NVS research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →
Register founding interest — Pro $29/mo or Power $79/mo
Paid plans aren’t for sale yet. Leave your email to lock founding pricing (Pro $29, Power $79); we’ll reach out personally.